Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
Author:
Funder
Incyte
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11523-022-00906-w.pdf
Reference45 articles.
1. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl. 1):19–31. https://doi.org/10.1111/liv.14095.
2. Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11:13–26. https://doi.org/10.5009/gnl15568.
3. Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, et al. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases. 2019;7:1732–52. https://doi.org/10.12998/wjcc.v7.i14.1732.
4. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8. https://doi.org/10.1182/blood-2013-03-488098.
5. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74. https://doi.org/10.1038/sj.bjc.6605779.
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers;JCO Precision Oncology;2024-08
2. Factors associated with prognosis and staging of intrahepatic cholangiocarcinoma;Journal of Cancer Metastasis and Treatment;2024-07-10
3. Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta‐analysis;Liver International;2024-06-03
4. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202;ESMO Open;2024-06
5. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives;Expert Review of Clinical Pharmacology;2024-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3